Modern subunit vaccines based on homogeneous antigens offer more precise targeting and
improved safety compared with traditional whole-pathogen vaccines. However, they are also …

mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells.
mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy …

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

Cancer remains the leading cause of death worldwide despite advances in treatment
options for patients. As such, safe and effective therapeutics are required. Short peptides …

Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis.
However, their aberrant overexpression and glycosylation in various malignancies facilitate …

Targeted drug delivery has improved cancer treatment significantly in recent years, although
it is difficult to achieve. Different approaches have been developed to apply targeted drug …

Mucins—large extracellular proteins that are heavily glycosylated with complex
oligosaccharides—establish a selective molecular barrier at the epithelial surface and …

Abstract Changes in glycosylation are often a hallmark of disease states. For example,
cancer cells frequently display glycans at different levels or with fundamentally different …

The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses
has stimulated research on harnessing DCs to create more effective vaccines. Early clinical …

Pancreatic cancer remains a lethal malignancy with poor prognosis owing to therapeutic
resistance, frequent recurrence and the absence of treatment strategies that specifically …